# Acrotech Biopharma Inc. clinical trials: 28 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials with Acrotech Biopharma Inc. as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Acrotech Biopharma Inc.: 28 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/acrotech-biopharma-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 25, 2025 | NCT07036133 | Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and... | Acrotech Biopharma Inc. | Phase 1 | Recruiting | Advanced Solid Tumors, Hematologic Malignancies | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07036133) |
| October 10, 2023 | NCT06072131 | To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL | Acrotech Biopharma Inc. | Phase 3 | Active not recruiting | Peripheral T Cell Lymphoma | 504 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06072131) |
| November 8, 2022 | NCT05608343 | This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD) | Acrotech Biopharma Inc. | Phase 3 | Completed | Atopic Dermatitis | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05608343) |
| October 7, 2022 | NCT05571943 | A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis | Acrotech Biopharma Inc. | Phase 3 | Completed | Atopic Dermatitis | 542 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05571943) |
| January 28, 2020 | NCT04243434 | PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients | Acrotech Biopharma Inc. | Phase 1 | Unknown | Hematologic Diseases | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04243434) |
| December 4, 2019 | NCT04184869 | Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials | Acrotech Biopharma Inc. | Phase 1 | Completed | Solid Tumor, Hematological Malignancies | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04184869) |
| February 12, 2016 | NCT02680795 | Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1\*28 Genotypes | Acrotech Biopharma Inc. | Phase 1 | Completed | Solid Tumors, Hematological Malignancies | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02680795) |
| February 10, 2016 | NCT02679131 | To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment. | Acrotech Biopharma Inc. | Phase 1 | Terminated | Relapsed/Refractory Solid Tumors/Hematological Malignancies | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02679131) |
| November 3, 2015 | NCT02594267 | A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) | Acrotech Biopharma Inc. | Phase 1 | Completed | Peripheral T-Cell Lymphoma (PTCL) | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02594267) |
| April 8, 2014 | NCT02106650 | Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies | Acrotech Biopharma Inc. | Phase 2 | Completed | Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02106650) |
| May 10, 2013 | NCT01851551 | Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL | Acrotech Biopharma Inc. | Phase 1/2 | Completed | Non-Hodgkin's Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01851551) |
| April 24, 2013 | NCT01839097 | Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) | Acrotech Biopharma Inc. | Phase 1 | Completed | Peripheral T-cell Lymphoma | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01839097) |
| March 28, 2013 | NCT01820091 | Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn® | Acrotech Biopharma Inc. | Phase 1 | Withdrawn | Non-Small Cell Lung Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01820091) |
| February 12, 2013 | NCT01789723 | Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn | Acrotech Biopharma Inc. | Phase 1 | Withdrawn | Non Hodgkin's Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01789723) |
| August 9, 2012 | NCT01660633 | Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation | Acrotech Biopharma Inc. | Phase 2 | Completed | Multiple Myeloma | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01660633) |
| April 24, 2012 | NCT01583777 | Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer | Acrotech Biopharma Inc. | Phase 1 | Completed | Advanced Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01583777) |
| March 8, 2011 | NCT01310244 | MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | Acrotech Biopharma Inc. | Phase 1/2 | Completed | Stage IV Non-small Cell Lung Cancer | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01310244) |
| October 18, 2010 | NCT01222780 | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | Acrotech Biopharma Inc. | Phase 1 | Completed | Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia, Lymphoma, Brain Tumors | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01222780) |
| June 2, 2010 | NCT01134341 | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | Acrotech Biopharma Inc. | Phase 1 | Completed | Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01134341) |
| May 7, 2010 | NCT01118624 | Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer | Acrotech Biopharma Inc. | Phase 2 | Completed | Breast Cancer, Breast Tumors, Neoplasms, Breast, Cancer of the Breast, Human Mammary Carcinoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01118624) |
| April 27, 2010 | NCT01110733 | Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry | Acrotech Biopharma Inc. | Observational | Completed | Peripheral T-cell Lymphoma | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01110733) |
| June 22, 2009 | NCT00925782 | PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation | Acrotech Biopharma Inc. | Phase 2 | Completed | Multiple Myeloma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00925782) |
| July 25, 2008 | NCT00722553 | Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder | Acrotech Biopharma Inc. | Phase 2 | Completed | Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00722553) |
| November 7, 2007 | NCT00554827 | Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | Acrotech Biopharma Inc. | Phase 1 | Completed | Cutaneous T-cell Lymphoma | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00554827) |
| June 4, 2007 | NCT00481871 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | Acrotech Biopharma Inc. | Phase 1/2 | Completed | Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell... | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00481871) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 4 |
| Phase 2 | 6 |
| Phase 3 | 3 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Withdrawn | 2 |
| Terminated | 1 |
| Active not recruiting | 1 |
| Unknown | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Lymphoma, T-Cell, Peripheral | 7 |
| Hematologic Neoplasms | 6 |
| Recurrence | 5 |
| Lymphoma | 5 |
| Lymphoma, Non-Hodgkin | 4 |
| Lymphoma, T-Cell | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Lymphoma, T-Cell, Cutaneous | 2 |
| Mycosis Fungoides | 2 |
| Sezary Syndrome | 2 |
| Leukemia | 2 |
| Multiple Myeloma | 2 |
| Dermatitis, Atopic | 2 |
| Neoplasm Metastasis | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Lung Neoplasms | 1 |
| Adenocarcinoma | 1 |
| Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 |
| Renal Insufficiency | 1 |
| Melanoma | 1 |
| Hematologic Diseases | 1 |
| Hodgkin Disease | 1 |
| Lymphoma, B-Cell | 1 |
| Waldenstrom Macroglobulinemia | 1 |
| Immunoblastic Lymphadenopathy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Moving companies in the United States](https://specstream.ai/data/businesses/moving-companies/united-states)
- [Appliance manufacturers in the United States](https://specstream.ai/data/businesses/appliance-manufacturers/united-states)
- [Gutter contractors in the United States](https://specstream.ai/data/businesses/gutter-contractors/united-states)
- [Solar installers in the United States](https://specstream.ai/data/businesses/solar-installers/united-states)
- [Cosmetic products manufacturers in the United States](https://specstream.ai/data/businesses/cosmetic-products-manufacturers/united-states)
- [Office supply stores in the United States](https://specstream.ai/data/businesses/office-supply-stores/united-states)
